PA
KRTX

Parallel Advisors’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Parallel Advisors’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-238
Closed -$75.3K – 3450
2023
Q4 		$75.3K Buy
238
+45
+23% +$8.75K ﹤0.01% 1244
2023
Q3 		$32.6K Hold
193
– – ﹤0.01% 1608
2023
Q2 		$41.9K Buy
193
+4
+2% +$857 ﹤0.01% 1489
2023
Q1 		$34.3K Sell
189
-3
-2% -$574 ﹤0.01% 1567
2022
Q4 		$37.7K Buy
192
+170
+773% +$36.5K ﹤0.01% 1406
2022
Q3 		$5K Buy
22
+3
+16% +$607 ﹤0.01% 2344
2022
Q2 		$2K Buy
+19
New +$2.18K ﹤0.01% 2672
2022
Q1 		– Sell
-1
Closed – – 3360
2021
Q4 		$0 Buy
+1
New +$129 ﹤0.01% 3359
2020
Q4 		– Sell
-4,965
Closed -$384K – 2767
2020
Q3 		$384K Hold
4,965
– – 0.02% 363
2020
Q2 		$553K Buy
+4,965
New +$432K 0.04% 274

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Parallel Advisors's KRTX Position: Q1 2024 in Review

Parallel Advisors sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 238 shares — an estimated $75.3K sold.

Parallel Advisors first reported a position in KRTX in Q2 2020 and held it in 10 quarters. The position peaked at $553K in Q2 2020. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Parallel Advisors reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Parallel Advisors sold 238 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $75.3K.
  • Parallel Advisors first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2020 and held it in 10 quarters.
  • Parallel Advisors's Karuna Therapeutics, Inc. Common Stock position peaked at $553K in Q2 2020.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Parallel Advisors's 13F filing for Q1 2024, filed 6 May 2024.